A phase 3 open-label study (IPASS) (120) found gefitinib to be more effective than carboplatin plus paclitaxel for initially treating lung adenocarcinoma in East Asian non-smokers or former mild smokers, suggesting that patients with EGFR mutations benefit most from gefitinib as a first-line treatment. This evidence concerns the gene EGFR and lung adenocarcinoma.